The management of C4C Group of Companies has issued a public rejoinder to clarify and correct an earlier statement made during the launch of one of its FDA-approved homoeopathic products.
The event, held as part of the World Homoeopathy Week Celebration, was aimed at unveiling a new milestone in the company’s contribution to holistic healthcare. However, C4C has since acknowledged an error in its claim that it had introduced “the first FDA-approved over-the-counter homoeopathic medicine” in Ghana.
Clarification
In an official rejoinder released by the company, and copied to the Chief Executive of the Food and Drugs Authority (FDA), C4C extended its sincere apologies, noting that the comment was made in error during a moment of enthusiasm surrounding its latest achievement.
“We acknowledge that this claim was inaccurate and regret any confusion or oversight it may have caused,” the statement read. “Having been corrected by the FDA, we wish to indicate that other homoeopathic medicines have previously been registered by the Authority and that C4C is not the first to do so.”
The company further clarified that its products were not registered as over-the-counter medications, as had earlier been implied.
“Indeed, our intention was never to disregard regulations but to celebrate a milestone in our own journey toward improving holistic healthcare access in the country,” the rejoinder explained.
C4C Group also reiterated its commitment to transparency, regulatory compliance, and stakeholder collaboration. It assured the public of its dedication to upholding the standards set by the Food and Drugs Authority and other relevant bodies.
Dr. Michael Kyeremateng, president of the C4C Group of Com
About The Author
